Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET/CT: a single-centre retrospective study.
Furosemide
PSMA
Prostate cancer
Sensitivity
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
27 Jul 2022
27 Jul 2022
Historique:
received:
06
05
2022
accepted:
09
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
High urinary activity in urinary bladder and ureters may hamper interpretation of prostate cancer and regional nodal metastases in prostate-specific membrane antigen (PSMA) PET/CT. The goal of this study was to assess effects of furosemide and choice of tracer on urinary activity in the bladder and ureters, as well as on occurrence of peri-bladder artefacts in PET/CT. Four cohorts with a total of 202 men staged with PSMA PET/CT for prostate cancer received either Median SUVmax bladder was 43,5; 14,8; 61,7 and 22,8 in cohorts G-, G+, F- and F+, respectively, resulting in significant overall (p < 0.001) and between cohort differences (p adjusted < 0.001 to 0.003) except between G- and F+. Median SUVmax ureter was 6.4; 4.5; 8.1 and 6.0 in cohorts G-, G+, F- and F+, respectively, resulting in significant overall (p < 0.001) and between cohort differences for G+ : F- and F- : F+ (p < 0.001, respectively, 0.019). Significant effects of furosemide and choice of tracer on SUVmax bladder (p < 0.001 resp. p = 0.001) and of furosemide on SUVmax ureter (p < 0.001) were found, whereas differences in biodistribution time had not impacted these results significantly. Peri-bladder artefacts were present in 42/202 (21%) patients and were significantly more frequent in the F- cohort, respectively, less frequent in the G+ cohort (p = 0.001 resp. p < 0.001). Peri-bladder artefacts had a direct positive correlation with SUVmax bladder (p = 0.033). Increased urinary activity and higher incidence of peri-bladder artefacts were found in
Sections du résumé
BACKGROUND
BACKGROUND
High urinary activity in urinary bladder and ureters may hamper interpretation of prostate cancer and regional nodal metastases in prostate-specific membrane antigen (PSMA) PET/CT. The goal of this study was to assess effects of furosemide and choice of tracer on urinary activity in the bladder and ureters, as well as on occurrence of peri-bladder artefacts in PET/CT.
METHODS
METHODS
Four cohorts with a total of 202 men staged with PSMA PET/CT for prostate cancer received either
RESULTS
RESULTS
Median SUVmax bladder was 43,5; 14,8; 61,7 and 22,8 in cohorts G-, G+, F- and F+, respectively, resulting in significant overall (p < 0.001) and between cohort differences (p adjusted < 0.001 to 0.003) except between G- and F+. Median SUVmax ureter was 6.4; 4.5; 8.1 and 6.0 in cohorts G-, G+, F- and F+, respectively, resulting in significant overall (p < 0.001) and between cohort differences for G+ : F- and F- : F+ (p < 0.001, respectively, 0.019). Significant effects of furosemide and choice of tracer on SUVmax bladder (p < 0.001 resp. p = 0.001) and of furosemide on SUVmax ureter (p < 0.001) were found, whereas differences in biodistribution time had not impacted these results significantly. Peri-bladder artefacts were present in 42/202 (21%) patients and were significantly more frequent in the F- cohort, respectively, less frequent in the G+ cohort (p = 0.001 resp. p < 0.001). Peri-bladder artefacts had a direct positive correlation with SUVmax bladder (p = 0.033).
CONCLUSIONS
CONCLUSIONS
Increased urinary activity and higher incidence of peri-bladder artefacts were found in
Identifiants
pubmed: 35895129
doi: 10.1186/s13550-022-00913-y
pii: 10.1186/s13550-022-00913-y
pmc: PMC9329505
doi:
Types de publication
Journal Article
Langues
eng
Pagination
42Informations de copyright
© 2022. The Author(s).
Références
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
J Med Imaging Radiat Oncol. 2017 Dec;61(6):739-744
pubmed: 28623852
Eur J Nucl Med Mol Imaging. 2014 May;41(5):887-97
pubmed: 24352789
AJR Am J Roentgenol. 2018 Sep;211(3):655-660
pubmed: 29873506
Cancer Imaging. 2019 May 15;19(1):23
pubmed: 31092293
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
J Nucl Med. 2021 Sep 1;62(9):1252-1257
pubmed: 33547214
J Nucl Med. 2021 Nov;62(11):1550-1557
pubmed: 33712533
Mol Imaging Biol. 2016 Jun;18(3):411-9
pubmed: 27080322
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95
pubmed: 23179945
PLoS One. 2021 Feb 2;16(2):e0246394
pubmed: 33529259
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):123-133
pubmed: 32385647
JAMA Oncol. 2019 Jun 01;5(6):856-863
pubmed: 30920593
Eur Radiol. 2016 Dec;26(12):4345-4353
pubmed: 27011373
Nucl Med Commun. 2019 Jun;40(6):652-656
pubmed: 30855543
PLoS One. 2017 Aug 17;12(8):e0183329
pubmed: 28817656